Penn clinicians and researchers are leaders in the diagnosis and treatment of thyroid cancer, and have published groundbreaking research in the development of molecularly targeted therapies such as sorafenib for the treatment of advanced thyroid cancer.
Penn researchers found patients with thyroid cancer that is resistant to radioactive iodine therapy were found to respond well to sorafenib. The phase II clinical trial data highlight an intensive effort at the Abramson Cancer Center to develop effective, personalized therapies for these patients, who have previously had few options for treatment. The program’s intensive lab-based efforts also developed an understanding of the molecular basis of the responses, so that future therapies can be tailored to every patient. The next phase of trials building on these findings is now under way.
Patients with thyroid cancer may be asked to participate in a variety of research studies. Learn more about participating in a clinical trial for head and neck cancer.